Pyxis Oncology Files Q1 2025 10-Q
Ticker: PYXS · Form: 10-Q · Filed: May 15, 2025 · CIK: 1782223
| Field | Detail |
|---|---|
| Company | Pyxis Oncology, Inc. (PYXS) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, partnerships
TL;DR
Pyxis Oncology's Q1 2025 10-Q is in, check out their Pfizer and Mabwell deals.
AI Summary
Pyxis Oncology, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including details on its Pfizer License Agreement and Mabwell Agreement. Key financial data and operational segments were also disclosed.
Why It Matters
This filing provides investors with an update on Pyxis Oncology's financial health and strategic partnerships, crucial for understanding the company's progress in drug development.
Risk Assessment
Risk Level: medium — Biotech companies like Pyxis Oncology are inherently risky due to the long and uncertain drug development process and regulatory hurdles.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 2025-05-15 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Filer of the 10-Q
- Pfizer License Agreement (company) — Key agreement mentioned
- Mabwell Agreement (company) — Key agreement mentioned
- Boston, MA (location) — Company headquarters
FAQ
What is the current status of Pyxis Oncology's drug development pipeline as of March 31, 2025?
The filing does not provide specific details on the current status of the drug development pipeline beyond mentioning key agreements like the Pfizer License Agreement and Mabwell Agreement.
What were the significant financial results for Pyxis Oncology in the first quarter of 2025?
The provided text is an excerpt from the header of the 10-Q and does not contain specific financial results for the first quarter of 2025.
Are there any new material agreements or amendments to existing agreements mentioned in this filing?
The filing references the Pfizer License Agreement and Mabwell Agreement, but does not specify if there were new material agreements or amendments in this excerpt.
What is the company's primary business focus?
Pyxis Oncology, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. is headquartered at 321 Harrison Avenue, Boston, MA 02118.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Pyxis Oncology, Inc. (PYXS).